Dupilumab 200 mg/1.14 mL, 300 mg/2 mL Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe/ Prefilled Pen)

Available Strengths: 200 mg/1.14 mL, 300 mg/2 mL

Reference Brands: Dupixent (USA)

Category: Immune Disorder

Dupilumab is a fully human monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4Rα), blocking the signaling of IL-4 and IL-13, key cytokines involved in type 2 inflammation. By modulating this immune pathway, Dupilumab helps control chronic immune-mediated conditions.

Product Description:

Dupilumab, marketed under the brand name Dupixent, is a fully human monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4Rα), thereby blocking IL-4 and IL-13 receptor signaling. These cytokines are central drivers of type 2 inflammation, which plays a key role in several chronic allergic and inflammatory conditions.

Dupilumab is approved for the treatment of moderate-to-severe atopic dermatitis (eczema), asthma, and chronic rhinosinusitis with nasal polyps. It is also indicated for other type 2 inflammatory disorders, including eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease (COPD). By inhibiting IL-4 and IL-13 signaling, dupilumab reduces inflammation, alleviates symptoms, improves skin and respiratory function, and enhances quality of life for patients with these conditions.

The medication is administered as a subcutaneous injection, typically every two weeks, with dosing adjusted based on the patient’s condition and weight. Clinical studies have demonstrated significant improvement in disease severity, symptom control, and long-term safety, making dupilumab an important therapeutic option for patients with type 2 inflammatory diseases.